Q1 Earnings Forecast for Stereotaxis Issued By Roth Capital

Stereotaxis, Inc. (NYSEAMERICAN:STXS - Free Report) - Analysts at Roth Capital reduced their Q1 2025 earnings per share estimates for Stereotaxis in a research report issued to clients and investors on Tuesday, March 4th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of ($0.07) per share for the quarter, down from their prior estimate of ($0.01). The consensus estimate for Stereotaxis' current full-year earnings is ($0.26) per share. Roth Capital also issued estimates for Stereotaxis' Q2 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.07) EPS.

Stereotaxis Stock Down 5.3 %

Shares of NYSEAMERICAN:STXS traded down $0.10 on Thursday, hitting $1.77. The stock had a trading volume of 578,894 shares, compared to its average volume of 456,751. The company has a market cap of $149.97 million, a P/E ratio of -6.32 and a beta of 1.54. The company has a 50 day moving average of $2.27. Stereotaxis has a twelve month low of $1.66 and a twelve month high of $3.29.

Insider Transactions at Stereotaxis

In other Stereotaxis news, Director Paul J. Isaac bought 23,299 shares of Stereotaxis stock in a transaction dated Thursday, March 6th. The shares were bought at an average price of $1.81 per share, with a total value of $42,171.19. Following the purchase, the director now owns 49,066 shares of the company's stock, valued at $88,809.46. This trade represents a 90.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 18.52% of the stock is owned by company insiders.

Remove Ads

Institutional Trading of Stereotaxis

Institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its holdings in Stereotaxis by 10.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 167,297 shares of the company's stock valued at $341,000 after purchasing an additional 15,491 shares during the period. State Street Corp raised its position in Stereotaxis by 5.7% in the third quarter. State Street Corp now owns 680,612 shares of the company's stock valued at $1,388,000 after purchasing an additional 36,518 shares during the last quarter. Jane Street Group LLC boosted its position in Stereotaxis by 26.9% during the 3rd quarter. Jane Street Group LLC now owns 29,773 shares of the company's stock worth $61,000 after buying an additional 6,313 shares during the period. Barclays PLC lifted its holdings in shares of Stereotaxis by 449.9% during the third quarter. Barclays PLC now owns 101,953 shares of the company's stock worth $208,000 after purchasing an additional 83,412 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Stereotaxis by 7.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,391,718 shares of the company's stock worth $2,840,000 after buying an additional 93,253 shares during the period. Institutional investors own 45.35% of the company's stock.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.